A projected cost-utility analysis of avacopan for the treatment of antineutrophil cytoplasmic antibody-associated vasculitis in Spain

References

• Sociedad Española de Reumatología. Manual SER de diagnóstico y tratamiento de las enfermedades reumáticas autoinmunes sistémicas. 1a ed. 2014.
   Google Scholar
• Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised international chapel hill consensus conference nomenclature of vasculitides. Arthritis Rheum. 2013;65(1):1–11. doi: 10.1002/art.37715
   PubMed Web of Science ®Google Scholar
• Romero-Gómez C, Aguilar-García JA, García-de-Lucas MD, et al. Epidemiological study of primary systemic vasculitides among adults in Southern Spain and review of the main epidemiological studies. Clin Exp Rheumatol. 2015;33(2 Suppl 89):S–8.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Garcia-Porrua C, Guerrero J, et al. The epidemiology of the primary systemic vasculitides in northwest Spain: implications of the Chapel Hill Consensus Conference definitions. Arthritis Rheum. 2003;49(3):388–393. doi: 10.1002/art.11115
   PubMed Web of Science ®Google Scholar
• Solans-Laqué R, Fraile G, Rodriguez-Carballeira M, et al. Clinical characteristics and outcome of Spanish patients with ANCA-associated vasculitides. Medicine. 2017;96(8):e6083. doi: 10.1097/MD.0000000000006083
   PubMed Web of Science ®Google Scholar
• Lionaki S, Hogan SL, Jennette CE, et al. The clinical course of ANCA small-vessel vasculitis on chronic dialysis. Kidney Int. 2009;76(6):644–651. doi: 10.1038/ki.2009.218
   PubMed Web of Science ®Google Scholar
• Marco H, Draibe J, Villacorta J, et al. Determinants of renal and patient outcomes in a Spanish cohort of patients with ANCA-associated vasculitis and renal involvement. Clin Rheumatol. 2018;37(4):1065–1074. doi: 10.1007/s10067-017-3973-2
   PubMed Web of Science ®Google Scholar
• Wester Trejo MAC, Floßmann O, Westman KW, et al. Renal relapse in antineutrophil cytoplasmic autoantibody-associated vasculitis: unpredictable, but predictive of renal outcome. Rheumatology. 2019;58(1):103–109. doi: 10.1093/rheumatology/key260
   PubMed Web of Science ®Google Scholar
• Slot MC, Tervaert JWC, Franssen CFM, et al. Renal survival and prognostic factors in patients with PR3-ANCA associated vasculitis with renal involvement. Kidney Int. 2003;63(2):670–677. doi: 10.1046/j.1523-1755.2003.00769.x
   PubMed Web of Science ®Google Scholar
• Yates M, Watts RA, Bajema IM, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016;75(9):1583–1594. doi: 10.1136/annrheumdis-2016-209133
   PubMed Web of Science ®Google Scholar
• Robson J, Doll H, Suppiah R, et al. Damage in the anca-associated vasculitides: long-term data from the European vasculitis study group (EUVAS) therapeutic trials. Ann Rheum Dis. 2015;74(1):177–184. doi: 10.1136/annrheumdis-2013-203927
   PubMed Web of Science ®Google Scholar
• Pujades-Rodriguez M, Morgan AW, Cubbon RM, et al. Dose-dependent oral glucocorticoid cardiovascular risks in people with immune-mediated inflammatory diseases: a population-based cohort study. PLOS Med. 2020;17(12):e1003432. doi: 10.1371/journal.pmed.1003432
   PubMed Web of Science ®Google Scholar
• Hellmich B, Sanchez-Alamo B, Schirmer JH, et al. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann Rheum Dis. 2023:ard-2022–223764. doi:10.1136/ard-2022-223764
   Google Scholar
• European Medicines Agency. Avacopan SmPC; 2022 [cited 2022 Dec 9]. Available from: https://www.ema.europa.eu/en/documents/product-information/tavneos-epar-product-information_en.pdf
   Google Scholar
• Jayne DRW, Merkel PA, Schall TJ, et al. Avacopan for the treatment of ANCA-Associated vasculitis. N Engl J Med. 2021;384(7):599–609. doi: 10.1056/NEJMoa2023386
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis [Internet]. 2022 [cited 2022 Dec 9]. Available from: https://www.nice.org.uk/guidance/ta825
   Google Scholar
• Gemeinsamer Bundesausschuss - the Federal Joint Committee. Resolution of the Federal Joint Committee on an amendment of the pharmaceuticals directive: annex XII – benefit assessment of medicinal products with new active ingredients according to section 35a SGB V avacopan (granulomatosis with polyangiitis or microscopic polyangiitis, combination with rituximab or cyclophosphamide). 2022.
   Google Scholar
• Haute Autorité de Santé (HAS). Avacopan, Tavneos 10mg capsuse first assessment adopted by the Transparency Committee on 21 September 2022. 2022.
   Google Scholar
• Ministerio de Sanidad. Puntos destacados de la reunión de la Comisión Interministerial de Precios de los Medicamentos - 15 de junio de 2023 [Internet]. 2023 [cited 2023 Jul 18]. Available from: https://www.sanidad.gob.es/areas/farmacia/precios/comisionInteministerial/acuerdosNotasInformativas/docs/NOTAINFORMATIVACIPM_JUNIO23.pdf
   Google Scholar
• Ortega Eslava A, Marín Gil R, Fraga Fuentes MD, et al. Guía de evaluación económica e impacto presupuestario en los informes de evaluación de medicamentos [Internet]. 2016 [cited 2023 Aug 11]. Available from: https://gruposdetrabajo.sefh.es/genesis/genesis/Documents/GUIA_EE_IP_GENESIS-SEFH_19_01_2017.pdf
   Google Scholar
• Stone JH, Merkel PA, Spiera R, et al. Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis. N Engl J Med. 2010;363(3):221–232. doi: 10.1056/NEJMoa0909905
   PubMed Web of Science ®Google Scholar
• Cui Z, Zhao J, Jia X, et al. Clinical features and outcomes of anti–glomerular basement membrane disease in older patients. Am J Kidney Diseases. 2011;57(4):575–582. doi: 10.1053/j.ajkd.2010.09.022
   PubMed Web of Science ®Google Scholar
• Instituto Nacional de Estadística. Tablas de mortalidad por año, sexo, edad y funciones. [Internet]. 2022 [cited 2022 Jul 25]. Available from: https://www.ine.es/jaxiT3/Tabla.htm?t=27153
   Google Scholar
• Wallace ZS, Lu N, Unizony S, et al. Improved survival in granulomatosis with polyangiitis: a general population-based study. Semin Arthritis Rheum. 2016;45(4):483–489. doi: 10.1016/j.semarthrit.2015.07.009
   PubMed Web of Science ®Google Scholar
• UK Renal Registry. UK renal registry 23rd annual report – data to 31/12/2019 [Internet]. Bristol (UK); 2021 [cited 2022 Dec 9]. Available from: https://ukkidney.org/sites/renal.org/files/23rd_UKRR_ANNUAL_REPORT.pdf
   Google Scholar
• Ministerio de Sanidad. Portal Estadístico del SNS - Registro de Altas de los Hospitales del Sistema Nacional de Salud. CMBD [Internet]. 2022 [cited 2022 Jul 26]. Available from: https://www.sanidad.gob.es/estadEstudios/estadisticas/cmbdhome.htm
   Google Scholar
• Gisbert R, Brosa M. Base de datos de costes sanitarios y ratios coste-efectividad españoles: eSalud [Internet]. 2007 [cited 2022 Apr 12]. Available from: http://www.oblikue.com/bddcostes/
   Google Scholar
• Alianza frente a la Poliquistosis Renal Autosómica Dominante. Libro Blanco de la Poliquistosis Renal Autosómica Dominante (PQRAD) en España [Internet]. 2016 [cited 2023 Aug 11]. Available from: https://senefro.org/contents/webstructure/noticias/LIBRO_PQRAD.pdf
   Google Scholar
• Bartra A, Caeiro J-R, Mesa-Ramos M, et al. Cost of osteoporotic hip fracture in Spain per autonomous region. Rev Esp Cir Ortop Traumatol. 2019;63(1):56–68. doi: 10.1016/j.recote.2018.11.004
   Google Scholar
• Lopez-Bastida J, Oliva Moreno J, Worbes Cerezo M, et al. Social and economic costs and health-related quality of life in stroke survivors in the Canary Islands, Spain. BMC Health Serv Res. 2012;12(1):315. doi: 10.1186/1472-6963-12-315
   PubMedGoogle Scholar
• Consejerías de Sanidad de las Comunidades Autónomas. Documento Marco sobre Enfermedad Renal Crónica (ERC) dentro de la Estrategia de Abordaje a la Cronicidad en el SNS. 2015 [cited 2023 Aug 11]. Available from: https://www.sanidad.gob.es/organizacion/sns/planCalidadSNS/pdf/Enfermedad_Renal_Cronica_2015.pdf
   Google Scholar
• Fernández-de-Bobadilla J, López-de-Sá E. Carga económica y social de la enfermedad coronaria. Rev Esp Cardiol Supl. 2013;13:42–47. doi: 10.1016/S1131-3587(13)70079-7
   Google Scholar
• Consejo General de Colegios Oficiales de Farmacéuticos. Portal Farma. BotPLUS [Internet]. 2023 [cited 2023 Aug 10]. Available from: https://botplusweb.portalfarma.com/botplus.aspx
   Google Scholar
• Ministerio de Sanidad. Listado de medicamentos afectados por las deducciones del Real Decreto-Ley 8/2010. Septiembre 2023 [Internet]. 2023 [cited 2023 Sep 10]. Available from: https://www.sanidad.gob.es/en/areas/farmacia/infoIndustria/infoDeducciones/ley8_2010/docs/Deducciones_Septiembre_23.pdf
   Google Scholar
• Instituto Nacional de Estadística. Encuesta Nacional de Salud (ENSE); 2017 [cited 2023 Aug 11]. Available from: https://www.ine.es/
   Google Scholar
• National Institute for Health and Care Excellence. Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody associated vasculitis [Internet]. 2014 [cited 2023 Aug 11]. Available from: https://www.nice.org.uk/Guidance/TA308
   Google Scholar
• National Institute for Health and Care Excellence. Patiromer for treating hyperkalaemia [internet]. 2020 [cited 2023 Aug 11]. Available from: https://www.nice.org.uk/guidance/TA623
   Google Scholar
• Instituto Nacional de Estadística. Encuesta Nacional de Salud (ENSE) 2011 [Internet]. 2011 [cited 2023 Aug 11]. Available from: https://www.ine.es/
   Google Scholar
• Sacristán JA, Oliva J, Campillo-Artero C, et al. ¿Qué es una intervención sanitaria eficiente en España en 2020? Gac Sanit. 2020;34(2):189–193. doi: 10.1016/j.gaceta.2019.06.007
   PubMed Web of Science ®Google Scholar
• Villacorta J, Diaz-Crespo F, Guerrero C, et al. Long-term validation of the renal risk score for vasculitis in a Southern European population. Clin Kidney J. 2021;14(1):220–225. doi: 10.1093/ckj/sfaa073
   PubMed Web of Science ®Google Scholar
• Husereau D, Drummond M, Augustovski F, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 explanation and elaboration: a report of the ISPOR CHEERS II good practices task force. Value Health. 2022;25(1):10–31. doi: 10.1016/j.jval.2021.10.008
   PubMed Web of Science ®Google Scholar
• Scott J, Canepa C, Buettner A, et al. A cohort study to investigate sex-specific differences in ANCA-associated glomerulonephritis outcomes. Sci Rep. 2021;11(1):13080. doi: 10.1038/s41598-021-92629-7
   PubMed Web of Science ®Google Scholar
• Mohammad AJ, Segelmark M. A population-based study showing better renal prognosis for Proteinase 3 antineutrophil cytoplasmic antibody (ANCA)–associated nephritis versus myeloperoxidase ANCA–associated nephritis. J Rheumatol. 2014;41(7):1366–1373. doi: 10.3899/jrheum.131038
   PubMed Web of Science ®Google Scholar
• Huang X, Chen L, Lan L, et al. Antineutrophil cytoplasmic antibody-associated vasculitis with acute kidney injury: short-term recovery predicts long-term outcome. Front Immunol. 2021;12:12. doi: 10.3389/fimmu.2021.641655
   Web of Science ®Google Scholar
• Booth AD, Almond MK, Burns A, et al. Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am J Kidney Diseases. 2003;41(4):776–784. doi: 10.1016/S0272-6386(03)00025-8
   PubMed Web of Science ®Google Scholar
• Powell T, O’Donell M. NICE appraisals of rare diseases [internet]. House Of Commons Library. 2019 [cited 2023 Aug 11]. Available from: https://researchbriefings.files.parliament.uk/documents/CDP-2019-0022/CDP-2019-0022.pdf
   Google Scholar
• Paulden M. Recent amendments to NICE’s value-based assessment of health technologies: implicitly inequitable? Expert Rev Pharmacoecon Outcomes Res. 2017;17(3):239–242. doi: 10.1080/14737167.2017.1330152
   PubMed Web of Science ®Google Scholar
• Ramirez de Arellano Serna A, Berdunov V, Baxter G. EE382 cost-utility analysis of avacopan for the treatment of anca-associated vasculitis (AAV) patients in the UK. Value Health. 2022;25(12):S130. doi: 10.1016/j.jval.2022.09.628
   Google Scholar
• Lakhdari K, Vicente C, Melnyk P, et al. EE519 cost effectiveness analysis of Avacopan in antineutrophil cytoplasm antibody-associated vasculitis - a Canadian perspective. Value Health. 2022;25(12):S157–S158. doi: 10.1016/j.jval.2022.09.760
   PubMed Web of Science ®Google Scholar
• Montante A, Le Bras A, Terrier B, et al. Economic evaluation of rituximab versus azathioprine for maintenance treatment of ANCA-associated vasculitis. A prospective, multicenter study. 2017 ACR/ARHP Annual Meeting; Nov 3–8; San Diego, CA; 2017. Abstract number: 1759.
   Google Scholar